Mig (Ibuprofen)

Ibuprofen, the active ingredient in Mig, is a Nonsteroidal anti-inflammatory drug (NSAID) presented as an oral tablet for oral use. It treats mild to moderate pain, fever, and inflammatory conditions such as arthritis in adults.

GNH USA supplies Mig as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ibuprofen acts systemically to reduce inflammation and pain across several common conditions.

Mild to moderate pain: provides analgesic relief for headaches, dental pain, musculoskeletal aches. Fever: lowers elevated body temperature in febrile states. Arthritis (inflammatory joint conditions): alleviates joint inflammation and associated discomfort.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Gastrointestinal upset, including nausea or dyspepsia. - Headache or dizziness. - Mild skin rash or itching.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Severe allergic reactions such as anaphylaxis. - Renal impairment or acute kidney injury. - Hepatic injury. - Cardiovascular events, including myocardial infarction or stroke. - Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before using Mig, consider the following safety measures.

Assess renal function: avoid in patients with severe renal impairment. Evaluate gastrointestinal risk: use with food or protective agents if a history of ulcer or bleeding. Monitor cardiovascular status: exercise caution in patients with heart disease or stroke risk. Avoid in third‑trimester pregnancy: consult a healthcare professional before use. Check for drug interactions: review all concomitant medications. Store at ambient temperature: keep in the original pack, protect from moisture.

Ibuprofen can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Selective COX‑2 inhibitors: additive gastrointestinal toxicity. - High‑dose corticosteroids: heightened ulcer risk. - Lithium: increased serum lithium concentrations. - Methotrexate: reduced clearance leading to toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may diminish renal function. - Diuretics: risk of renal impairment. - SSRIs or SNRIs: increased bleeding tendency. - Alcohol: enhances gastrointestinal irritation. - Cyclosporine: increased nephrotoxicity.